Evaluation of a microplate latex agglutination method (Verotox-F assay) for detecting and characterizing verotoxins (Shiga toxins) in Escherichia coli

Journal of Clinical Microbiology

Volumn 37, Issue 2, 1999, Pages 396-399

  Karmali, Mohamed A ^a,b   Petric, Martin ^a,b   Bielaszewska, Martina ^c  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

SHIGA TOXIN; VEROTOXIN;

ACCURACY; ARTICLE; ASSAY; CROSS REACTION; CYTOTOXICITY; ESCHERICHIA COLI; INTERMETHOD COMPARISON; LATEX AGGLUTINATION TEST; NONHUMAN; PERFORMANCE; PRIORITY JOURNAL; TOXIN ANALYSIS; VERO CELL;

EID: 0032927710     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/jcm.37.2.396-399.1999     Document Type: Article

References (33)

1. Beutin, L., S. Zimmermann, and K. Gleier. 1996. Rapid detection and isolation of Shiga-like toxin (Verocytotoxin)-producing Eacherichia coli by direct testing of individual enterohemolytic colonies from washed sheep blood agar plates in the VTEC-RPLA assay. J. Clin. Microbiol. 34:2812-2814.
2. Bielaszewska, M., J. Janda, K. Bláhová, L. Šrámková, J. Havlík, and V. Potužník. 1994. Vero cytotoxin-producing Escherichia coli in children with hemolytic uremic syndrome and diarrhea in the Czech Republic, p. 37-40. In M. A. Karmali and A. G. Goglio (ed.). Recent advances in verocytotoxin-producing Escherichia coli infections. Elsevier Science, Amsterdam, The Netherlands.
3. Bielaszewska, M., J. Janda, K. Bláhová, J. Feber, V. Potužník, and A. Součková. 1996. Verocytotoxin-producing Escherichia coli in children with hemolytic uremic syndrome in the Czech Republic. Clin. Nephrol. 46:42-44.
4. Bielaszewska, M., I. Clarke, M. A. Karmali, and M. Petric. 1997. Localization of intravenously administered verocytotoxins (Shiga-like toxins) 1 and 2 in rabbits immunized with homologous and heterologous toxoids and toxin subunits. Infect. Immun. 65:2509-2516.
5. Calderwood, S. B., D. W. K. Acheson, G. T. Keusch, T. J. Barrett, P. M. Griffin, N. A. Strockbine, B. Swaminathan, J. B. Kaper, M. M. Levine, B. S. Kaplan, H. Karch, A. D. O'Brien, T. G. Obrig, Y. Takeda, P. I. Tarr, and I. K. Wachsmuth. 1996. Proposed new nomenclature for Shiga-like toxin (verotoxin) family. ASM News 62:118-119.
6. DeGrandis, S. A., J. Ginsberg, M. Toone, S. Climie, J. Friesen, and J. Brunton. 1987. Nucleotide sequence and promoter mapping of the Escherichia coli Shiga-like toxin operon of bacteriophage H-19B. J. Bacteriol. 169:4313-4319.
7. Feng, P. 1997. Impact of molecular biology on the detection of foodborne pathogens. Mol. Biotechnol. 7:267-268.
8. Griffin, P. M., and R. V. Tauxe. 1991. The epidemiology of infections caused by Escherichia coli OI57:H7, other enterohemorrhagic E. coli, and the associated hemolytic uremic syndrome. Epidemiol. Rev. 13:60-98.
9. Head, S. C., M. A. Karmali, M. E. Roscoe, M. Petric, N. A. Strockbine, and I. K. Wachsmuth. 1988. Serological differences between verocytotoxin 2 and Shiga-like toxin II. Lancet ii:751.
10. Head, S. C., M. Petric, S. Richardson, M. Roscoe, and M. A. Karmali. 1988. Purification and characterization of verocytotoxin 2. FEMS Microbiol. Lett. 51:211-216.
11. Hii, J. H., C. Gyles, T. Morooka, M. A. Karmali, R. Clarke, S. DeGrandis, and J. L. Brunton. 1991. Development of verotoxin 2-and verotoxin 2 variant (VT2v)-specific oligonucleotide probes on the basis of the nucleotide sequence of the B cistron of VT2v from Escherichia coli E32511 and B2F1. J. Clin. Microbiol. 29:2704-2709.
12. Karch, H., T. Meyer, H. Rüssmann, and J. Heesemann. 1992. Frequent loss of Shiga-like toxin genes in clinical isolates of Escherichia coli upon subcultivation. Infect. Immun. 60:3464-3467.
13. Karmali, M., M. Winkler, M. Petric, C. McDowell, and L. Penn. 1995. Evaluation of a microplate latex method (VEROTOX-F) in Escherichia coli, abstr. C-178, p. 32. In Abstracts of the 95th General Meeting of the American Society for Microbiology 1995. American Society for Microbiology, Washington, D.C.
14. Karmali, M. A., M. Petric, C. Lim, P. C. Fleming, G. S. Arbus, and H. Lior. 1985. The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J. Infect. Dis. 151:775-782.
15. Karmali, M. A., M. Winkler, and M. Petric. 1994. Evaluation of a microplate latex method (Verotox-F) for detecting and characterizing verotoxins (VT) in Escherichia coli, abstr. O-Z. In Abstracts of the 62nd Conjoint meeting on Infectious Diseases.
16. Karmali, M. A. 1989. Infection by verocytotoxin-producing Escherichia coli. Clin. Microbiol. Rev. 2:15-38.
17. Karmali, M. A., M. Petric, M. Winkler, M. Bielaszewska, J. Brunton, N. van de Kar, T. Morooka, G. B. Nair, S. E. Richardson, and G. S. Arbus. 1994. Enzyme-linked immunosorbent assay for detection of immunoglobulin G antibodies to Escherichia coli Vero cytotoxin 1. J. Clin. Microbiol. 32:1457-1463.
18. Kehl, K. S., P. Havens, C. E. Behnke, and D. W. K. Acheson. 1997. Evaluation of the Premier EHEC assay for detection of Shiga toxin-producing Escherichia coli. J. Clin. Microbiol. 35:2051-2054.
19. Konowalchuk, J., J. I. Speirs, and S. Stavric. 1977 Vero response to a cytotoxin of Escherichia coli. Infect. Immun. 18:775-779.
20. Mangan, K. (Denka Seiken Company, Ltd.). Personal communication.
21. Morooka, T., M. Petric, G. S. Arbus, M. Winkler, and M. A. Karmali. 1994. Distribution of Verocytotoxins (Shiga-like toxins) among clinical isolates of Verocytotoxin-producing Escherichia coli. Med. Bull. Fukuoka Univ. 21:263-268.
22. O'Brien, A. D., M. A. Karmali, and S. M. Scotland. 1994. A proposal for rationalizing the nomenclature of the Escherichia coli cytotoxins, p. 147-149. In M. A. Karmali and A. G. Goglio (ed.). Recent advances in verocytotoxin-producing Escherichia coli infections. Elsevier Science, Amsterdam, The Netherlands.
23. Obrig, T. G., P. J. D. Vecchio, J. E. Brown, T. P. Moran, B. M. Rowland, T. K. Judge, and S. W. Rothman. 1988. Direct cytotoxic action of Shiga toxin on human vascular endothelial cells. Infect. Immun. 56:2373-2378.
24. Petric, M., M. A. Karmali, S. Richardson, and R. Cheung. 1987 Purification and biological properties of Escherichia coli verocytotoxin. FEMS Microbiol. Lett. 41:63-68.
25. Pierard, D., L. Huyghens, and S. Lauwers. 1991 Diarrhoea associated with Escherichia coli producing porcine oedema disease verotoxin. Lancet 338: 762.
26. Pollard, D. R., W. M. Johnson, H. Lior, S. D. Tyler, and K. R. Rozee. 1990. Differentiation of Shiga toxin and Vero cytotoxin type 1 genes by polymerase chain reaction. J. Infect. Dis. 162:1195-1198.
27. Richardson, S. E., M. A. Karmali, L. E. Becker, and C. R. Smith. 1988. The histopathology of the hemolytic uremic syndrome associated with verocytotoxin-producing Escherichia coli infections. Hum. Pathol. 19:1102-1108.
28. Richardson, S. E., T. A. Rotman, V. Jay, C. R. Smith, L. E. Becker, M. Petric, N. F. Olivieri, and M. A. Karmali. 1992. Experimental verocytotoxemia in rabbits. Infect. Immun. 60:4154-4167.
29. Rüssmann, H., H. Schmidt, J. Heesemann, A. Caprioli, and H. Karch. 1994. Variants of Shiga-like toxin II constitute a major toxin component in Escherichia coli O157 strains from patients with haemolytic uraemic syndrome. J. Med. Microbiol. 40:338-343.
30. Scotland, S. M., H. R. Smith, and B. Rowe. 1985. Two distinct toxins active on Vero cells from Escherichia coli O157:H7. Lancet ii:885-886.
31. Thomas, A., H. R. Smith, and B. Rowe. 1993. Use of digoxigenin-labelled oligonucleotide DNA probes for VT2 and VT2 variant genes to differentiate Vero cytotoxin-producing Escherichia coli strains of serogroup 0157. J. Clin. Microbiol. 31:1700-1703.
32. Thomas, A., T. Cheasty, H. Chart, and B. Rowe. 1994. Isolation of Vero cytotoxin-producing Escherichia coli serotype O9ab:H-carrying VT2 variant gene sequences from a patient with haemolytic uraemic syndrome. Eur. J. Microbiol. Infect. Dis. 13:1074-1076.
33. Tyler, S. D., W. M. Johnson, H. Lior, G. Wang, and K. R. Rozee. 1991. Identification of verotoxin type 2 variant B subunit genes in Escherichia coli by the polymerase chain reaction and restriction fragment length polymorphism analysis. J. Clin. Microbiol. 29:1339-1343.